| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
PF-5006739 targets casein kinase 1δ (CK1δ) and casein kinase 1ε (CK1ε) with IC50 values of 3.9 nM and 17.0 nM, respectively. It shows low nanomolar in vitro potency against CK1δ/ε and high kinome selectivity. CK1δ/ε are involved in the regulation of circadian rhythms, Wnt signaling, and various psychiatric and metabolic processes.
|
|---|---|
| ln Vitro |
In vitro, PF-5006739 demonstrates potent inhibition of CK1δ (IC50 = 3.9 nM) and CK1ε (IC50 = 17.0 nM) with high kinome selectivity. At concentrations of 0.4-50 µM for 5 days, PF-5006739 induces rapid, dose-dependent bioluminescence in WAT tissue explants. These properties support its use in psychiatric disorder research.
|
| ln Vivo |
In vivo, PF-5006739 (10 mg/kg/day, s.c., once daily) significantly improves glycemic status in diet-induced obesity (DIO) mice. It improves glucose tolerance in both DIO and genetic (ob/ob) mouse models of obesity. The compound dose-dependently reduces opioid drug-seeking behavior in a rodent operant reinstatement model.
|
| Enzyme Assay |
Specific cell-free enzyme/receptor binding assay protocols for PF-5006739 involve CK1δ/ε kinase activity assays. IC50 values of 3.9 nM (CK1δ) and 17.0 nM (CK1ε) are determined using purified enzymes and appropriate substrates. Kinome selectivity is confirmed by screening against a panel of kinases.
|
| Cell Assay |
In vitro cell-based assays for PF-5006739 use WAT tissue explants to assess its effects on circadian rhythms. Explants are treated with PF-5006739 (0.4-50 µM for 5 days), and mPER2::luc bioluminescence is measured to assess dose-dependent induction. Kinase selectivity is confirmed using cell-based kinase panel assays.
|
| Animal Protocol |
In vivo animal studies for PF-5006739 have been conducted in rodent models of obesity and drug-seeking behavior. In DIO and ob/ob mice, subcutaneous administration at 10 mg/kg/day improves glucose tolerance. In a rodent operant reinstatement model, the compound dose-dependently reduces opioid-seeking behavior.
|
| ADME/Pharmacokinetics |
PF-5006739 has a molecular formula of C22H22FN7O and a molecular weight of 419.45 g/mol. It is soluble in DMSO at 80 mg/mL (190.73 mM). Purity is ≥98% (HPLC). Storage: at +4°C. The compound has a CAS number of 1293395-67-1.
|
| Toxicity/Toxicokinetics |
Specific toxicological data for PF-5006739 are not detailed in the available literature. The compound is classified for research use only and is not intended for human therapeutic applications. As a CK1δ/ε inhibitor, potential toxicities would relate to effects on circadian rhythms and Wnt signaling, though formal toxicological profiles are not reported.
|
| References | |
| Additional Infomation |
PF-5006739 (CAS 1293395-67-1) is a potent and selective CK1δ/ε inhibitor with IC50 values of 3.9 nM (CK1δ) and 17.0 nM (CK1ε). It shows high kinome selectivity and is used in psychiatric disorder research. In vivo, it reduces opioid-seeking behavior and improves glucose tolerance in obesity models. No clinical trial data are available.
|
| Molecular Formula |
C22H22FN7O
|
|---|---|
| Molecular Weight |
419.4644
|
| Exact Mass |
419.186
|
| CAS # |
1293395-67-1
|
| PubChem CID |
51353555
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
680.9±65.0 °C at 760 mmHg
|
| Flash Point |
365.6±34.3 °C
|
| Vapour Pressure |
0.0±2.1 mmHg at 25°C
|
| Index of Refraction |
1.718
|
| LogP |
2.26
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
31
|
| Complexity |
570
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
XPWHRQHBPRSUAW-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C22H22FN7O/c23-16-3-1-15(2-4-16)20-21(19-5-9-25-22(24)27-19)30(14-26-20)18-6-10-29(11-7-18)13-17-8-12-31-28-17/h1-5,8-9,12,14,18H,6-7,10-11,13H2,(H2,24,25,27)
|
| Chemical Name |
4-[5-(4-fluorophenyl)-3-[1-(1,2-oxazol-3-ylmethyl)piperidin-4-yl]imidazol-4-yl]pyrimidin-2-amine
|
| Synonyms |
PF5006739; PF 5006739; PF-5006739
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~238.41 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.96 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.96 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3840 mL | 11.9201 mL | 23.8402 mL | |
| 5 mM | 0.4768 mL | 2.3840 mL | 4.7680 mL | |
| 10 mM | 0.2384 mL | 1.1920 mL | 2.3840 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
